Altimmune, Inc.

Good day, ladies and gentlemen. Welcome to the Altamune Inc. First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. To ask a question during the session, you will need to press star 1-1 on your telephone. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, Rich Eisenstadt, Chief Financial Officer of Altimmune. Rich, you may begin.

Thank you, Gigi, and good morning, everyone. Thank you for participating in Altimmune's first quarter 2023 financial results and business update conference call. Members of the Altimmune team joining me on the call today are Vipin Garg, our Chief Executive Officer, Scott Roberts, our Chief Scientific Officer, and Scott Harris, our Chief Medical Officer. Following the prepared remarks, we will hold a question and answer session. A press release with our first quarter 2023 financial results was issued this morning and can be found on the investor relations section of the company's website. Before we begin, I would like to remind everyone that remarks about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. also mean cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For discussion of some of the risks and factors that could affect the company's future results and operations, please see the risk factors and other cautionary statements contained in the company's filing with the SEC. I would also direct you to read the forward-looking statement disclaimer in our press release issued this morning and now available on our website. Any statements made on this conference call speak only as of today's date, Thursday, May 11th, 2023, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this conference call is being recorded and will be available for audio replay on Altamine's website. With that, I will now turn the call over to Dr. Griffin Garrett, Chief Executive Officer of Altimmune.

Thank you, Rich, and good morning, everyone. We appreciate you joining us today for a discussion of our first quarter 2023 financial results and business update. We continue to advance our lead product candidate, Pembidutide, a GLP-1 glucodone dual receptor agonist in development for both obesity and NASH. Late last year, we announced compelling 24-week data from our trial in subjects with NASH-LB, and we plan to initiate the IMPACT Phase 2B NASH trial mid-year 2023. We believe that the effects of pembidutide on liver fat are class-leading. We also believe that pembidutide is the only NASH candidate in development that combines robust reductions in both liver fat and body weight. This is extremely important because NASH patients suffer not only from the complications of liver disease, but also from the underlying problem of obesity, a principal driver of NASH. Scott Harris will provide more details on the impact of trials shortly. With regards to obesity, We look forward to reporting top nine 48-week weight loss data from our phase two momentum obesity trial in the fourth quarter of this year. The momentum interim results of 160 subjects reported earlier this year showed weight loss of 10.7% at the 2.4 milligram dose and 9.4% at the 1.8 milligram dose compared to 1% weight loss in subjects receiving placebo after only 24 weeks. These robust reductions in body weight together with the effects of pembidutide on serum lipids and blood pressure suggest that pembidutide has the potential to be an important treatment option for patients with obesity, especially individuals with NASLD and dyslipidemia. Enrollment in the phase two clinical trial of hep T cell in chronic hepatitis B is now complete, and we expect to have a data readout in the first quarter of 2024. Recall that this trial is designed to show evidence of antiviral effects of HBV and establish its role in combination therapy for the treatment of this important disease. We're excited about the progress at Family G-Side and at PCL and the upcoming results of these ongoing trials. With that, I'll now turn the call over to our Chief Medical Officer, Dr. Scott Harris, to discuss our clinical plans. Scott?